Sensei Biotherapeutics (NASDAQ:FTH) Given “Buy” Rating at Needham & Company LLC

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They presently have a $56.00 target price on the stock. Needham & Company LLC‘s target price would suggest a potential upside of 474.54% from the company’s previous close.

Several other research firms have also weighed in on FTH. Guggenheim cut their target price on Sensei Biotherapeutics from $70.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. William Blair initiated coverage on Sensei Biotherapeutics in a research note on Friday, October 16th. They set an “outperform” rating for the company. Lifesci Capital raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, October 15th. Citizens Jmp initiated coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $56.58.

Read Our Latest Analysis on FTH

Sensei Biotherapeutics Price Performance

Shares of FTH stock traded down $0.28 on Monday, hitting $9.75. The company’s stock had a trading volume of 133,878 shares, compared to its average volume of 286,625. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $42.14. The firm’s fifty day moving average price is $25.07. The firm has a market cap of $251.90 million, a PE ratio of -0.07 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). As a group, equities analysts predict that Sensei Biotherapeutics will post -14.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of FTH. State of Wyoming acquired a new stake in shares of Sensei Biotherapeutics in the third quarter valued at about $25,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Sensei Biotherapeutics by 48.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock worth $150,000 after purchasing an additional 1,760 shares during the period. AWM Investment Company Inc. increased its stake in shares of Sensei Biotherapeutics by 4.5% in the third quarter. AWM Investment Company Inc. now owns 116,344 shares of the company’s stock worth $3,460,000 after purchasing an additional 5,001 shares during the period. Citadel Advisors LLC bought a new stake in Sensei Biotherapeutics during the 2nd quarter valued at approximately $307,000. Finally, Renaissance Technologies LLC boosted its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.

Further Reading

Analyst Recommendations for Sensei Biotherapeutics (NASDAQ:FTH)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.